Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Silence Therapeutics plc (Nasdaq: SLN), a clinical-stage biotechnology company specializing in novel siRNA (short interfering RNA) therapies, has announced its participation in a fireside chat at the Jefferies Global Healthcare Conference. This event is scheduled for November 19, 2025, at 8:00 a.m. ET (1:00 p.m. GMT) in London. Investors and interested parties can access the live webcast via the Investors section of the Silence Therapeutics website, with an archived replay available after the conference.

Silence Therapeutics stands at the forefront of innovative medical research with its proprietary mRNAi GOLD™ platform, which focuses on precision-engineered siRNAs meant to target and silence disease-related genes, particularly within the liver. This approach highlights a significant opportunity for developing therapies aimed at various conditions, especially in fields with considerable unmet medical needs such as cardiovascular diseases, hematology, and rare diseases.

The company's commitment to transforming lives through its advanced medicine solutions underscores its mission in the biotechnology landscape. By leveraging cutting-edge RNA interference technology, Silence Therapeutics strives to deliver effective treatments that could potentially alter the course of diseases previously deemed challenging to treat.

As the company prepares for the Jefferies conference, it aims to showcase its advancements and innovations in the siRNA space, further establishing itself as a leader in biotech solutions. Stakeholders, analysts, and healthcare enthusiasts are encouraged to engage with the webcast to gain insights into the company’s latest developments and strategic direction.

For further information about Silence Therapeutics and their innovative work, interested parties can visit their website at [www.silence-therapeutics.com](https://www.silence-therapeutics.com/).

Silence Therapeutics plc (Nasdaq: SLN) is poised to leverage its participation in the upcoming Jefferies Global Healthcare Conference in London as a significant platform to enhance investor visibility and showcase its innovative siRNA therapies. Scheduled for November 19, 2025, this event represents an excellent opportunity for the company to discuss its pipeline and strategic direction, particularly in addressing high unmet medical needs in areas such as cardiovascular disease and hematology.

Investors should closely monitor the insights shared during the fireside chat, as such platforms often provide critical updates on clinical trials, partnerships, and market strategies that could impact the stock's valuation. Silence's proprietary mRNAi GOLD™ platform enables the development of tailored siRNA therapies, a cutting-edge approach in the competitive biotechnology landscape. Given the increasing investor appetite for innovative therapeutics, Silence's focus on precision medicine could resonate well with the market.

Additionally, this conference offers Silence Therapeutics an opportunity to outline its advancements and competitive positioning against other biotechnology firms. The live webcast will be accessible through Silence's website, making it more convenient for stakeholders to participate and engage with the management team.

As the market evolves, stakeholders should assess how Silence articulates its value proposition, especially regarding upcoming clinical data releases and potential licensing deals. Currently, analysts recommend a cautious yet optimistic stance. Investing in Silence Therapeutics could yield substantial rewards should its therapeutic candidates demonstrate efficacy in upcoming trials. Therefore, it is advisable for investors to stay tuned for developments emerging from the conference and consider adjusting their positions accordingly based on the company's strategic goals outlined during this key event.